177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry

#2880

Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.

Aim(s): The aim was to describe the characteristics of patients and advanced somatostatin receptor–positive neuroendocrine tumours (TNE) treated with 177Lu-DOTATATE (PRRT) and to evaluate the efficacy and safety.

Materials and methods: The data come from the SEPTRALU national study in which a multidisciplinary team of 18 centers participate. Survival was evaluated using the Kaplan-Meier method and Cox proportional risk regression. Toxicity was recorded according to CTCAEv3.0 criteria.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carmona Bayonas A

Authors: Carmona-Bayonas A, Mitjavila Casanovas M, Belló P, Percovich J, Prieto A,

Keywords: PRRT, 177Lu-DOTATATE, radionuclide,

To read the full abstract, please log into your ENETS Member account.